|1.||Correll, Christoph U: 74 articles (12/2015 - 01/2004)|
|2.||Leucht, Stefan: 66 articles (11/2015 - 02/2002)|
|3.||Citrome, Leslie: 59 articles (10/2014 - 01/2002)|
|4.||Kane, John M: 58 articles (12/2015 - 01/2002)|
|5.||Lieberman, Jeffrey A: 54 articles (01/2015 - 02/2002)|
|6.||Meltzer, Herbert Y: 53 articles (08/2015 - 01/2002)|
|7.||Ascher-Svanum, Haya: 45 articles (07/2014 - 01/2004)|
|8.||Remington, Gary: 42 articles (09/2015 - 01/2002)|
|9.||Uchida, Hiroyuki: 41 articles (09/2015 - 10/2003)|
|10.||Suzuki, Takefumi: 36 articles (09/2015 - 10/2003)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2014 - "Some of the most significant problems encountered in the treatment of schizophrenia are non-adherence to the treatment with oral neuroleptics and difficult recovery of social functioning, after its impairment by negative psychotic symptoms and the progression of the disease with episodes of remission and relapse. "
06/01/2013 - "Existing antipsychotic drugs are most effective in the treatment of the positive symptoms of schizophrenia. "
03/01/2012 - "Antipsychotic drugs for the treatment of schizophrenia arrived in the clinic in the fifties of the previous century and have since been the most effective treatment for patients with this devastating disorder. "
01/01/2011 - "Understanding the genetic variation affecting response to antipsychotics is important to develop novel diagnostic tests to match individual schizophrenia patients to the most effective and safe medication. "
12/01/2009 - "Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first- or second-generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained."
|2.||Bipolar Disorder (Mania)
07/01/2010 - "Most second-generation antipsychotics have demonstrated efficacy in the treatment of mania, both in monotherapy and as adjuncts to mood stabilizers. "
12/01/2011 - "The atypical antipsychotic drugs are considered a first-line treatment for mania in bipolar disorder with many having a proven superiority to the classical mood stabilisers. "
12/01/2011 - "The second-generation antipsychotics, with their proven efficacy against manic symptoms, are emerging as candidates for use against the depressive phase of bipolar disorder. "
01/01/2005 - "The atypical antipsychotics, with their proven efficacy against manic symptoms, are emerging as candidates for use against the depressive phase of bipolar disorder. "
01/01/2005 - "Atypical antipsychotics appear to have broadly similar efficacy against manic symptoms of bipolar disorder, but there are important differences in their tolerability profiles, which are likely to be of particular relevance during long-term treatment. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
04/01/2011 - "Although it is likely that most, if not all, antipsychotics are effective for schizoaffective disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of schizoaffective disorder, greater attention is now being focused on the entity of schizoaffective disorder and potential treatment decisions. "
06/01/2003 - "While efficacious, their side-effects have been problematic and the approval by the Food and Drug Administration of the newer antipsychotics with improved side-effects profiles heralded important advances in treating psychoses. "
04/01/1991 - "The acute psychoses did not improve with moderate doses of major tranquilizers but resolved completely with drug discontinuation."
05/01/2013 - "Up to now, studies have not demonstrated significant efficacy of antipsychotics on cognitive impairments in patients with psychotic disorders. "
10/01/2004 - "The appearance of the atypical antipsychotics has come as a true 'revolution' in their treatment, owing to the good results obtained in the treatment of the psychoses and the scant deterioration of the motor signs of PD."
|4.||Movement Disorders (Movement Disorder)
12/01/1982 - "Ironically, neuroleptics are the most consistently effective treatment of tardive dyskinesia. "
02/01/1999 - "The arrival of atypical antipsychotics has markedly improved the outlook: atypical antipsychotics are emerging as effective treatments and may also reduce the prevalence and incidence of tardive dyskinesia. "
04/01/2011 - "Moreover, recent reports suggest that atypical antipsychotics may have a beneficial effect on tardive dyskinesia remission. "
01/01/2006 - "Treatment with RLAI significantly improved disease symptoms, functioning, hospitalization status, and reduced movement disorders, in psychotic patients considered clinically stable on oral atypical antipsychotics. "
01/01/2002 - "However, the significant improvement caused by the withdrawal of antipsychotic drugs in Pisa syndrome differentiates it from tardive dystonia. "
04/01/2014 - "Physicians may justly consider antipsychotics to be the best option for some dementia patients among available nonpharmacologic and pharmacologic treatments. "
04/01/2008 - "There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. "
01/01/2015 - "However, high adverse events may offset the efficacy of atypical antipsychotics in dementia."
05/01/2000 - "Traditional neuroleptics have been the mainstay of treatment for agitated behavior in persons with dementia, but these agents have limited efficacy and are associated with high rates of adverse effects, including worsening of already poor cognitive functioning. "
01/01/2014 - "The higher risks for AEs and mortality may offset the efficacy of atypical antipsychotics for treatment of dementia. "
|1.||Risperidone (Risperdal Consta)
|4.||Antipsychotic Agents (Antipsychotics)
|5.||Antidepressive Agents (Antidepressants)
|1.||Drug Therapy (Chemotherapy)